(Press-News.org) SAN DIEGO (March 15, 2015) -- Patients taking evolocumab--an investigational therapy previously shown to dramatically lower "bad" cholesterol--were half as likely to die, suffer a heart attack or stroke, be hospitalized or need a procedure to open blocked arteries compared with those who received standard care, according to research presented at the American College of Cardiology's 64th Annual Scientific Session in San Diego.
In this open-label study, the rate of cardiovascular events was 2.18 percent after one year in the standard of care group, most of whom were on moderate or high intensity statin therapy. In contrast, patients treated with evolocumab had approximately half the risk or a 0.95 percent event rate after one year.
Previous trials have shown the drug can substantially lower low-density lipoprotein cholesterol, known as LDL or "bad" cholesterol because it contributes to plaque, a thick, hard deposit that can clog arteries and make them less flexible. Evolocumab reduced bad cholesterol by 61 percent. Evolocumab is a human monoclonal antibody that works by blocking proprotein convertase subtilisin-kexin 9 (PCSK9), a protein that reduces the liver's ability to remove LDL cholesterol from the blood.
"The reduction in LDL was profound and that may be why we saw a marked reduction in cardiovascular events so quickly," said Marc Sabatine, M.D., chairman of the TIMI Study Group and a senior physician in the Division of Cardiovascular Medicine at Brigham and Women's Hospital in Boston, and the study's lead author. "It suggests that if we can drive a patient's LDL cholesterol down a large amount to a very low level, we may start to see a benefit sooner than would be expected with a more modest intervention."
At the start of the study, the average LDL cholesterol measure was 120 milligrams per deciliter, which is similar to the average LDL cholesterol level among Americans. Patients receiving evolocumab were able to achieve an absolute reduction of more than 70 milligrams per deciliter reaching 48 milligrams per deciliter on average. Sabatine said this achieved level of LDL cholesterol is much lower than that achieved in the treatment arm of most other trials.
Researchers studied a total of 4,465 patients who, upon completing one of 12 phase II or III trials that evaluated the drug's ability to lower LDL cholesterol, subsequently enrolled in this one-year extension study to investigate the therapy's effect on long-term safety, LDL-lowering and cardiovascular outcomes. Researchers re-randomized patients 2:1 to receive evolocumab injected under the skin either every two or four weeks plus standard care, or standard care alone, which consisted of the lipid-lowering therapy recommended by their treating physician, usually moderate or high-intensity statin therapy. A central committee that was blinded to the treatment groups then reviewed the data and reported the number of deaths, major coronary events, heart attack, stroke, unstable angina requiring hospitalization and coronary revascularization.
The 53 percent reduction in cardiovascular events in the evolocumab group was consistent across each of the major cardiovascular events included in the composite endpoint--death, heart attack, stroke, hospitalization and angioplasty--and among patient subgroups; no differences were found based on age, baseline LDL levels, statin use, primary or secondary prevention or whether they had valve disease.
Adverse events were largely balanced between the two-week and four-week treatment arms and evolocumab was well-tolerated.
Still, the results are limited by the nature of the trial, in which there were relatively few cardiovascular outcomes (only 60). An ongoing, highly anticipated trial of 27,500 patients to investigate evolocumab's effect on cardiovascular outcomes is underway; however, data are not expected until 2017. But, as Sabatine explained, between now and then there will be a two-year gap in data at a time when this drug may be available for clinical use pending review by the U.S. Food and Drug Administration later this year.
"We won't have any definitive answers until this larger trial we are doing is complete, but these data now give us a sense for the potential clinical benefit of these drugs," Sabatine said. "We know from previous research that evolocumab lowers LDL cholesterol, but these data offer support for their potential to reduce major adverse cardiovascular events in our patients."
The drug makes sense biologically too, he said. "Patients who genetically have lower levels of PCSK9 activity also have a lower rate of adverse cardiovascular outcomes. Now in our analyses, we see this PCSK9 inhibitor appears to reduce adverse cardiovascular outcomes."
He said the findings are especially good news for patients who, despite taking a statin, are not able to lower LDL cholesterol enough or who cannot tolerate statins for a variety of reasons. Evolocumab is one of three PCSK9 inhibitors being studied in large clinical trials.
One out of three American adults is estimated to have high LDL cholesterol, according to the Centers for Disease Control and Prevention. Elevated LDL cholesterol is recognized as a major risk factor for cardiovascular disease, which remains the leading cause of death worldwide.
INFORMATION:
This study was funded by Amgen, the manufacturer of the drug.
This study was simultaneously published in the New England Journal of Medicine at the time of presentation.
The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC15 for the latest news from the meeting.
The American College of Cardiology is a 49,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more information, visit acc.org.
SAN DIEGO (March 15, 2015) -- The SAPIEN 3 heart valve demonstrated lower death, stroke and paravalvular leak rates than earlier generation devices in patients at high risk for surgery and showed encouraging results in intermediate-risk patients, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Transcatheter aortic valve replacement, known as TAVR, is approved for patients with severe aortic stenosis--narrowing of the valve in the heart's main artery--whose health profile makes them ineligible or high-risk candidates ...
SAN DIEGO (March 15, 2015) -- An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement seems to improve in-hospital safety outcomes and cognitive scores at discharge, according to preliminary findings from a small randomized study presented at the American College of Cardiology's 64th Annual Scientific Session.
The valve replacement procedure, known as TAVR, dislodges minute particles from the clogged valve, freeing them to float through the bloodstream. Much of this debris travels "downstream" from the heart, but ...
SAN DIEGO (March 15, 2015) -- Five-year data suggest that the SAPIEN transcatheter heart valve is a feasible option for patients with severe aortic stenosis deemed to be at high risk for open-heart surgery, though valve leakage was more common with the first-generation valve evaluated in this study than with surgery, according to research from PARTNER I presented at the American College of Cardiology's 64th Annual Scientific Session.
When the blockage of an aortic valve becomes severe, replacement is the only real treatment choice, but many elderly and frail people are ...
SAN DIEGO (March 15, 2015) -- Two-year data show a continued survival advantage for self-expanding transcatheter aortic valve replacement (TAVR) over standard surgery in high-risk patients with severe aortic stenosis, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Aortic stenosis--a problem that occurs when the valve in the heart's main artery doesn't open fully--forces the heart to work harder to pump blood and is life-threatening over time. Valve replacement is common when this condition becomes severe, but the ...
SAN DIEGO (March 15, 2015) --The commercial track record with transcatheter mitral valve repair, approved for patients at high risk for surgery, compares favorably with pre-approval reports, according to findings from a U.S. registry presented at the American College of Cardiology's 64th Annual Scientific Session.
Healthy valves function as one-way gates that keep blood moving forward through the heart. Severely damaged mitral valves don't close properly, allowing blood to leak backward. If the valve isn't repaired or replaced, the condition can cause serious health ...
Police are ill-equipped to investigate non-criminal deaths and face a challenge to avoid re-traumatising bereaved families as well as emotionally protecting themselves, according to QUT research.
Investigating death: the emotional and cultural challenges for police found it was usually junior officers sent to sudden death investigations and tasked with not only gathering evidence, but also comforting family members and explaining the coronial process.
The research has been published in the journal of Policing and Society.
"The vast majority of deaths are neither ...
NEW YORK, NY - Researchers have built a new computational tool that identifies 800 different ways people are at increased risk for post-traumatic stress disorder (PTSD), permitting for the first time a personalized prediction guide.
Results from the study out of NYU Langone Medical Center are published online (date) in the journal BMC Psychiatry.
"Our study shows that high-risk individuals who have experienced a traumatic event can be identified less than two weeks after they are first seen in the emergency department," says Arieh Y. Shalev, MD, the Barbara Wilson ...
NEW YORK, March 15, 2015 - Most physicians are aware of the importance of lifestyle factors in preventing cardiovascular disease (CVD) -- and believe diet is as important as statin therapy and exercise, according to a new survey from NYU Langone Medical Center.
Researchers found that a majority of doctors would welcome additional training in diet and nutrition so that they can effectively inform patients on the subject. The study will be presented at the American College of Cardiology's 64th Annual Scientific Session as a poster presentation.
The 28-question online survey, ...
NEW YORK, March 4, 2015 - Air pollution has been linked to a dangerous narrowing of neck arteries that occurs prior to strokes, according to researchers at NYU Langone Medical Center.
The scientists analyzed medical test records for more than 300,000 people living in New York, New Jersey or Connecticut. They found that people living in zip codes with the highest average levels of fine-particulate-matter pollution were significantly more likely to show signs of narrowing (stenosis) in their internal carotid arteries, compared to those living in zip codes with the lowest ...
March 16, 2015, New York, NY - Exploring the fundamental mechanism by which a cell-surface receptor transmits its signal, an international team of Ludwig researchers and their colleagues has established proof of concept for an entirely new approach to drug design. They report that a class of synthetic molecules known as diabodies can, from outside the cell, latch onto a target receptor and manipulate it in such a manner as to induce distinct and varying effects within cells and tissues. Led by Christopher Garcia of Ludwig Stanford, the researchers show in lab experiments ...
